OPC-21268 hydrate

• Catalog No.: O1016
• CAS Number: 131631-89-5(anhydrous)
• M. F.: C26H33N3O5
• M. W.: 467.55732
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: N-(3-{4-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy}propyl)acetamide hydrate
• IUPAC Traditional name: N-(3-{4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy}propyl)acetamide hydrate
• Synonyms: N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-acetamide hydrate; 1-{1-[4(3-acetylaminopropoxy)benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone hydrate

DATABASE IDS

• MDL Number: MFCD18632552
• CAS Number: 131631-89-5(anhydrous)

PROPERTIES

• Empirical Formula (Hill Notation): C26H31N3O4 · xH2O
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: DMSO: ≥20 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H400
• European Hazard Symbols: Harmful (Xn)
• European Hazard Symbols: Nature polluting (N)
• GHS Precautionary statements: P273
• Risk Statements: 22-50
• Safety Statements: 61
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (简体中文)

Biochem/physiol Actions
OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.

Description (English)

Biochem/physiol Actions
OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.